Matt Wasserman - Concepedia

Author

Matt Wasserman

Pfizer (United States)ORCID

Also Known As

M Wasserman, M. Wasserman, Matt D Wasserman, Matt D. Wasserman, Matt Wasserman, Matthew D. Wasserman, Matthew Wasserman

Publications

901

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)RTI Health Solutions Pfizer (Canada)Pfizer (United Kingdom)

About

Matt Wasserman is an author at Pfizer (United States) specializing in medicine, epidemiology, and public health.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	352
2	Public Health	4	4	141
3	Business	1	1	77
4	Education	1	1	13
5	Health Sciences	1	1	77

Matt Wasserman

Publications

662

Citations

H-Index

Page 1

	Year	Citations
Long-term uncoupling of chloride secretion from intracellular calcium levels by lns(3,4,5,6)P4 M. Vajanaphanich, Carsten Schultz, Marco T. Rudolf, Nature Protein SecretionSignal TransductionMolecular PhysiologyBiochemistryIntracellular Calcium Levels	1994	198
Understanding the economic impact of intravascular ultrasound (IVUS) Alessandro Alberti, Pietro Giudice, A. Gelera, The European Journal of Health Economics EconomicsMedical UltrasoundApplied EconomicsHealth EconomicsBusiness	2015	77
Ten year public health impact of 13-valent pneumococcal conjugate vaccination in infants: A modelling analysis Ruth Chapman, Kelly Sutton, Desmond Dillon-Murphy, Vaccine VaccinationVaccine SafetyPreventive MedicinePediatric EpidemiologyMedicine	2020	47
Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States Liping Huang, Matt Wasserman, Lindsay R. Grant, Vaccine VaccinationVaccine SafetyPediatric EpidemiologyPcv13 SerotypesMedicine	2022	44
Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age Matt Wasserman, Johnna Perdrizet, Lindsay R. Grant, Infectious Diseases and Therapy	2021	40
Increased hospital length of stay attributable to Clostridium difficile infection in patients with four co-morbidities: an analysis of hospital episode statistics in four European countries Christian Eckmann, Matt Wasserman, Faisal Latif, The European Journal of Health Economics Healthcare-associated InfectionClinical EpidemiologyPatient SafetyHospital LengthEuropean Countries	2013	39
Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada Michele Wilson, Matt Wasserman, Taj Jadavi, Infectious Diseases and Therapy	2018	34
Dynamic transmission modelling to address infant pneumococcal conjugate vaccine schedule modifications in the UK Matt Wasserman, A. O. Lucas, Dylan Jones, Epidemiology and Infection	2018	24
Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China Kunling Shen, Matt Wasserman, Dongdong Liu, PLoS ONE	2018	24
Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico Matt Wasserman, María G. Palacios, Ana Gabriela Grajales, Human Vaccines & Immunotherapeutics	2018	24

Page 1